BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Multiple Myeloma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Multiple Myeloma\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b/
 2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinati
 ons With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\,
  and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973605-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b/
 2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinati
 ons With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\,
  and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04973605-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b
 /2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinat
 ions With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\
 , and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated prima
 ry completion: November 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-c
 ell Redirectors as Part of First Line Treatment in Transplant Eligible Mul
 tiple Myeloma Patients\nEstimated primary completion: November 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T
 -cell Redirectors as Part of First Line Treatment in Transplant Eligible M
 ultiple Myeloma Patients\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517017-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06517017)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Use of Isatu
 ximab\, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frai
 l Patients With Multiple Myeloma\nEstimated primary completion: November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0651701
 7
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517017-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06517017)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Use of Isatuxi
 mab\, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail 
 Patients With Multiple Myeloma\nEstimated primary completion: November 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06517017
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182696-3263@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:OriCAR-017: Phase 1/2 readout est. (NCT06182696)
DESCRIPTION:OriCAR-017\, phase 1/2\, Multiple Myeloma.\nStudy: OriCAR-017 C
 himeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
 \nEstimated primary completion: 30 November 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/oricar-017#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06182696
URL:https://assetmemo.bio/drug/oricar-017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05299424-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT05299424)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: A S
 tudy of CM336 in Patients With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05299424
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of E
 lotuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed M
 ultiple Myeloma\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Elo
 tuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed Mul
 tiple Myeloma\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02718833-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT02718833)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Elo
 tuzumab With Pomalidomide\, Bortezomib\, and Dexamethasone in Relapsed Mul
 tiple Myeloma\nEstimated primary completion: December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02718833
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05396885-3142@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anitocabtagene autoleucel: Phase 2 readout est. (NCT05396885)
DESCRIPTION:Anitocabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Mye
 loma (iMMagine-1)\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05396885
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421675-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06421675)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient an
 d Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myelo
 ma\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06421675
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832865-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06832865)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: ELISA in Relap
 sed/Refractory MM\nEstimated primary completion: 1 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06832865
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015542-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06015542)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Self-administ
 ration of Subcutaneous Elranatamab in the Patients' Homes.\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06015542
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832865-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06832865)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ELISA in Rela
 psed/Refractory MM\nEstimated primary completion: 1 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06832865
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\,
  Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dex
 amethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma
  (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\, 
 Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and Dexa
 methasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma 
 (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03729804-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261228
DTEND;VALUE=DATE:20261229
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03729804)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Carfilzomib\
 , Lenalidomide\, and Dexamethasone Versus Bortezomib\, Lenalidomide and De
 xamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myelom
 a (COBRA)\nEstimated primary completion: 28 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03729804
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514990-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT05514990)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Bortezomib a
 nd Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed 
 or Refractory Multiple Myeloma\, AMBUSH Trial\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05514990
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05565807-3172@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:STI-6129: Phase 1/2 readout est. (NCT05565807)
DESCRIPTION:STI-6129\, phase 1/2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refract
 ory Multiple Myeloma\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sti-6129#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05565807
URL:https://assetmemo.bio/drug/sti-6129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776330-3425@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech): Phas
 e 1/2 readout est. (NCT04776330)
DESCRIPTION:BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)\,
  phase 1/2\, Multiple Myeloma.\nStudy: a Clinical Research of BCMA-Targete
 d Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Pla
 sma Cell Disease\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bcma-targeted-prime-car-t-cel
 ls-chongqing-precision-biotech#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04776330
URL:https://assetmemo.bio/drug/bcma-targeted-prime-car-t-cells-chongqing-pr
 ecision-biotech#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, 
 Carfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0488
 3242
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Carfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relap
 sed or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 883242
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04883242-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04883242)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, C
 arfilzomib\, Pomalidomide\, and Dexamethasone for the Treatment of Relapse
 d or Refractory Multiple Myeloma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048832
 42
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764861-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07764861)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Open-Label 
 Phase in Participants With Multiple Myeloma\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07764861
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764861-3193@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI3003: Phase 2 readout est. (NCT07764861)
DESCRIPTION:IBI3003\, phase 2\, Multiple Myeloma.\nStudy: A Open-Label Phas
 e in Participants With Multiple Myeloma\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibi300
 3#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 764861
URL:https://assetmemo.bio/drug/ibi3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822972-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2 readout est. (NCT06822972)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: HCMT/MM2401: Ph
 2 Study of Selinexor + Bispecific Antibody for RRMM\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06822972
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or
  Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0186
 3550
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib or 
 Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With 
 Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT018635
 50
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01863550-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT01863550)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Bortezomib o
 r Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients Wit
 h Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT01
 863550
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827860-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06827860)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Subcutaneous 
 Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06827860
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05932680-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05932680)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Limited-durat
 ion Teclistamab\nEstimated primary completion: January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05932680
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827860-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06827860)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Subcutaneous 
 Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06827860
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Mezigdomide: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Mezigdomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalido
 mide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or
  Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mezigdomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 19085
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05519085-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05519085)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Mezigdomide\, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidom
 ide\, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or 
 Refractory Multiple Myeloma (RRMM)\nEstimated primary completion: 10 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05519
 085
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wit
 h Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0426
 8498
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wit
 h Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0426
 8498
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Dar
 atumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients With
  Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042684
 98
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wi
 th Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 268498
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04508790-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04508790)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Leflunomide\
 , Pomalidomide\, and Dexamethasone for the Treatment of Relapsed or Refrac
 tory Multiple Myeloma\nEstimated primary completion: 14 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04508790
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535244-3151@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05535244)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation An
 tigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myelom
 a\nEstimated primary completion: 26 February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05535244
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of JN
 J-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed A
 gainst B-cell Maturation Antigen (BCMA) in Participants With Multiple Myel
 oma\nEstimated primary completion: 26 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of JNJ
 -68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Ag
 ainst B-cell Maturation Antigen (BCMA) in Participants With Multiple Myelo
 ma\nEstimated primary completion: 26 February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of J
 NJ-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed 
 Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Mye
 loma\nEstimated primary completion: 26 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of JNJ-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Ther
 apy Directed Against B-cell Maturation Antigen (BCMA) in Participants With
  Multiple Myeloma\nEstimated primary completion: 26 February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ciltacabtagene-autoleucel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041336
 36
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166565-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04166565)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab C
 ombined With Bortezomib\, Cyclophosphamide and Dexamethasone for the Treat
 ment of Multiple Myeloma Patients Presenting With Extramedullary Disease\n
 Estimated primary completion: March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04166565
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166565-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04166565)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab Co
 mbined With Bortezomib\, Cyclophosphamide and Dexamethasone for the Treatm
 ent of Multiple Myeloma Patients Presenting With Extramedullary Disease\nE
 stimated primary completion: March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04166565
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06952478)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Da
 rzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patien
 ts With Refractory or Relapsed Multiple Myeloma\nEstimated primary complet
 ion: 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06952478
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-3384@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:CT-P44: Phase 3 readout est. (NCT06952478)
DESCRIPTION:CT-P44\, phase 3\, Multiple Myeloma.\nStudy: A Study to Compare
  Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Darzale
 x Faspro in Combination With Lenalidomide and Dexamethasone in Patients Wi
 th Refractory or Relapsed Multiple Myeloma\nEstimated primary completion: 
 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p44#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0695
 2478
URL:https://assetmemo.bio/drug/ct-p44#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523555-3374@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech BCMA/CD19 dual-target CAR-T: Phase 1/2 readout est.
  (NCT07523555)
DESCRIPTION:Beijing Biotech BCMA/CD19 dual-target CAR-T\, phase 1/2\, Multi
 ple Myeloma.\nStudy: Adaptive Dual-Target CAR-T Cells for Relapsed or Refr
 actory Hematologic Malignancies\nEstimated primary completion: 14 March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech-b
 cma-cd19-dual-target-car-t#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07523555
URL:https://assetmemo.bio/drug/beijing-biotech-bcma-cd19-dual-target-car-t#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523555-3375@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech BCMA/CD38 dual-target CAR-T: Phase 1/2 readout est.
  (NCT07523555)
DESCRIPTION:Beijing Biotech BCMA/CD38 dual-target CAR-T\, phase 1/2\, Multi
 ple Myeloma.\nStudy: Adaptive Dual-Target CAR-T Cells for Relapsed or Refr
 actory Hematologic Malignancies\nEstimated primary completion: 14 March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech-b
 cma-cd38-dual-target-car-t#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07523555
URL:https://assetmemo.bio/drug/beijing-biotech-bcma-cd38-dual-target-car-t#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07523555-3376@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Beijing Biotech BCMA/GPRC5D dual-target CAR-T: Phase 1/2 readout es
 t. (NCT07523555)
DESCRIPTION:Beijing Biotech BCMA/GPRC5D dual-target CAR-T\, phase 1/2\, Mul
 tiple Myeloma.\nStudy: Adaptive Dual-Target CAR-T Cells for Relapsed or Re
 fractory Hematologic Malignancies\nEstimated primary completion: 14 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/beijing-biotech
 -bcma-gprc5d-dual-target-car-t#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07523555
URL:https://assetmemo.bio/drug/beijing-biotech-bcma-gprc5d-dual-target-car-
 t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study 
 to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated 
 primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/venetoclax#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ixazomib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Ixazomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Evalu
 ate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated primary 
 completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ixazomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04068597
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2849@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Inobrodib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Inobrodib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study t
 o Evaluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/inobrodib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study to E
 valuate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prim
 ary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Teclistamab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Teclistamab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Eva
 luate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated primar
 y completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study to E
 valuate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prim
 ary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Clinical S
 tudy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus P
 omalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma P
 atients\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508983-3173@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sanritatug: Phase 3 readout est. (NCT06508983)
DESCRIPTION:Sanritatug\, phase 3\, Multiple Myeloma.\nStudy: A Clinical Stu
 dy Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pom
 alidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Pat
 ients\nEstimated primary completion: 31 March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/sanritatug#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06508983
URL:https://assetmemo.bio/drug/sanritatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853965-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT05853965)
DESCRIPTION:Venetoclax\, phase 1/2\, Multiple Myeloma.\nStudy: Combination 
 Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed 
 and Refractory t(11\;14) Multiple Myeloma\nEstimated primary completion: A
 pril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 53965
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and
  Backbone Treatments of Multiple Myeloma Patients\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 linexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02343042
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ixazomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Ixazomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and 
 Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comple
 tion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixa
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02343042
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 mezigdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor 
 and Backbone Treatments of Multiple Myeloma Patients\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02343042
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor an
 d Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 ortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02343042
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor 
 and Backbone Treatments of Multiple Myeloma Patients\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02343042
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor an
 d Backbone Treatments of Multiple Myeloma Patients\nEstimated primary comp
 letion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 lotuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02343042
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Se
 linexor and Backbone Treatments of Multiple Myeloma Patients\nEstimated pr
 imary completion: April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02343042
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853965-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05853965)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Co
 mbination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of
  Relapsed and Refractory t(11\;14) Multiple Myeloma\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 belantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05853965
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patient
 s Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Ib
 erdomide\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Isatuximab: Phase 3 readout est. (NCT05558319)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: NDMM Patients 
 Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iber
 domide\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05558319)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: NDM
 M Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs.
  Isa-V-Iberdomide\nEstimated primary completion: April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to In
 vestigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib a
 nd Dexamethasone in Adult Participants With Relapsed and/or Refractory Mul
 tiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Pomalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory
  Multiple Myeloma\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, P
 omalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835129-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04835129)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, P
 omalidomide\, Elotuzumab and Dexamethasone in Relapsed and/or Refractory M
 ultiple Myeloma\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04835129
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Isatuximab: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib an
 d Dexamethasone in Adult Participants With Relapsed and/or Refractory Mult
 iple Myeloma\nEstimated primary completion: 1 April 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to I
 nvestigate the Clinical Benefit of Isatuximab in Combination With Bortezom
 ib\, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multipl
 e Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT033
 19667
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03319667-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03319667)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Inv
 estigate the Clinical Benefit of Isatuximab in Combination With Bortezomib
 \, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple 
 Myeloma Not Eligible for Transplant\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0331966
 7
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05354557-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05354557)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Stu
 dy of Iberdomide in People With Multiple Myeloma Who Have Had an Autologou
 s Hematopoietic Stem Cell Transplant (AHCT)\nEstimated primary completion:
  26 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberd
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05354557
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02420860-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT02420860)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Elotuzumab a
 nd Lenalidomide After Stem Cell Transplant in Treating Patients With Newly
  Diagnosed Multiple Myeloma\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02420860
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02420860-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elotuzumab: Phase 2 readout est. (NCT02420860)
DESCRIPTION:Elotuzumab\, phase 2\, Multiple Myeloma.\nStudy: Elotuzumab and
  Lenalidomide After Stem Cell Transplant in Treating Patients With Newly D
 iagnosed Multiple Myeloma\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02420860
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02960555-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Isatuximab: Phase 2 readout est. (NCT02960555)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab Wit
 h or Without Lenalidomide in Patients With High Risk Smoldering Multiple M
 yeloma (ISAMAR)\nEstimated primary completion: 30 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02960555
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carf
 ilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04176718
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 tumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04176718
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\
 , Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pom
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04176718
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801939-3151@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Cevostamab: Phase 2 readout est. (NCT05801939)
DESCRIPTION:Cevostamab\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab Fol
 lowing CAR T Cell Therapy for RRMM\nEstimated primary completion: May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05801939
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05393804-3314@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Idecabtagene vicleucel: Phase 2 readout est. (NCT05393804)
DESCRIPTION:Idecabtagene vicleucel\, phase 2\, Multiple Myeloma.\nStudy: A 
 Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple My
 eloma Who Have Had a Hematopoietic Cell Transplant\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ide
 cabtagene-vicleucel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05393804
URL:https://assetmemo.bio/drug/idecabtagene-vicleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627751-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT06627751)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Mezigdomide\,
  Carfilzomib\, and Dexamethasone for the Treatment of Relapsed or Refracto
 ry Multiple Myeloma in Patients With Extramedullary Disease\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06627751
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627751-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT06627751)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: Mezigdomide\,
  Carfilzomib\, and Dexamethasone for the Treatment of Relapsed or Refracto
 ry Multiple Myeloma in Patients With Extramedullary Disease\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06627751
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06566547-3438@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Velinotamig (GR1803): Phase 2 readout est. (NCT06566547)
DESCRIPTION:Velinotamig (GR1803)\, phase 2\, Multiple Myeloma.\nStudy: GR18
 03 Injection in Patients With Relapsed/Refractory Multiple Myeloma\nEstima
 ted primary completion: 12 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/velinotamig-gr1803#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06566547
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03346135-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03346135)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab A
 fter Stem Cell Transplant in Treating Patients With Multiple Myeloma\nEsti
 mated primary completion: 17 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03346135
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Schedule\, and Evaluate the Safety and 
 Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Par
 ticipants With Relapsed and/or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mezigdomide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06988488
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087653-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT06087653)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Safety\, E
 fficacy\, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in 
 Multiple Myeloma (MM)\nEstimated primary completion: 31 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06087653
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06988488-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT06988488)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Schedule\, and Evaluate the Safety and 
 Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Par
 ticipants With Relapsed and/or Refractory Multiple Myeloma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06988488
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of 
 Carfilzomib\, Lenalidomide\, Vorinostat\, and Dexamethasone in Relapsed an
 d/or Refractory Multiple Myeloma\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of
  Carfilzomib\, Lenalidomide\, Vorinostat\, and Dexamethasone in Relapsed a
 nd/or Refractory Multiple Myeloma\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Study of Venet
 oclax in Combination With Carfilzomib and Dexamethasone in Participants Wi
 th Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02899052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Vene
 toclax in Combination With Carfilzomib and Dexamethasone in Participants W
 ith Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carf
 ilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02899052
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Study of Tecl
 istamab in Combination in Elderly Patients With Multiple Myeloma\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Study of Tecl
 istamab in Combination in Elderly Patients With Multiple Myeloma\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Study of Tec
 listamab in Combination in Elderly Patients With Multiple Myeloma\nEstimat
 ed primary completion: June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715478-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT03715478)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Multi-Cent
 er Study of GSK2857916 in Combination With Pomalidomide and Dex\nEstimated
  primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03715478
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03715478-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT03715478)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Mu
 lti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex\nE
 stimated primary completion: 1 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03715478
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266441-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Ramantamig: Phase 2 readout est. (NCT07266441)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study of JNJ
 -79635322 in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 14 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07266441
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333509-3231@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:CT071: Phase 1/2 readout est. (NCT06333509)
DESCRIPTION:CT071\, phase 1/2\, Multiple Myeloma.\nStudy: Anti-GPRC5D CAR-T
  Cells (CT071) in Participants With RRMM or RRpPCL\nEstimated primary comp
 letion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ct071#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06333509
URL:https://assetmemo.bio/drug/ct071#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phas
 e 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horiz
 en-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336472-3193@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:IBI3003: Phase 1/2 readout est. (NCT07336472)
DESCRIPTION:IBI3003\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of IBI3
 003 in Subjects With Relapsed or Refractory Multiple Myeloma\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ibi3003#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07336472
URL:https://assetmemo.bio/drug/ibi3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909826-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05909826)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Carfilzomib\,
  Oral Cyclophosphamide\, and Dexamethasone for RRMM\nEstimated primary com
 pletion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05909826
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04634552-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Talquetamab: Phase 2 readout est. (NCT04634552)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ta
 lquetamab in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04634552
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Seli
 nexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With Re
 lapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07479
 979
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Se
 linexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With 
 Relapsed and/or Refractory Multiple Myeloma\nEstimated primary completion:
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7479979
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Sel
 inexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With R
 elapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 79979
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients With
  Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Tr
 ansplantation\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients With
  Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Tr
 ansplantation\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of C
 arfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients Wit
 h Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell T
 ransplantation\nEstimated primary completion: July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05346809-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05346809)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab Dur
 ing Stem Cell Collection and Transplant in Patients With Multiple Myeloma 
 and Lymphoma\nEstimated primary completion: July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05346809
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06183489-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06183489)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Use of Elrana
 tamab in Patients With High-risk Smoldering Multiple Myeloma\nEstimated pr
 imary completion: July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06183489
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-3168@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HLX15: Phase 3 readout est. (NCT06895512)
DESCRIPTION:HLX15\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evaluate
  the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with
  Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/hlx15#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06895512
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04124497-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04124497)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Trial for R
 elapsed and Relapsed/Refractory Multiple Myeloma Patients\nEstimated prima
 ry completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04124497
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04124497-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04124497)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Trial for 
 Relapsed and Relapsed/Refractory Multiple Myeloma Patients\nEstimated prim
 ary completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04124497
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648459-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07648459)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
 -SOC for Dynamically High-Risk Multiple Myeloma Study\nEstimated primary c
 ompletion: 9 July 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/gamgertamig-cm336#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07648459
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/darat
 umumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study Comp
 aring Talquetamab in Combination With Daratumumab or in Combination With D
 aratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalid
 omide and Dexamethasone in Participants With Multiple Myeloma That Returns
  After Treatment or is Resistant to Treatment\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/poma
 lidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05455320
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Talquetamab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talqu
 etamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04497961-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04497961)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of He
 alth-Related Quality of Life in People With Multiple Myeloma Receiving Dar
 atumumab or Lenalidomide\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04497961
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02538198-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT02538198)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Lenalidomide
  Maintenance in Plasma Cell Myeloma\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT025381
 98
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04497961-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04497961)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of H
 ealth-Related Quality of Life in People With Multiple Myeloma Receiving Da
 ratumumab or Lenalidomide\nEstimated primary completion: August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04497961
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05972135)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient Ad
 ministration of Teclistamab or Talquetamab for Multiple Myeloma\nEstimated
  primary completion: August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05972135
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Talquetamab: Phase 2 readout est. (NCT05972135)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient Ad
 ministration of Teclistamab or Talquetamab for Multiple Myeloma\nEstimated
  primary completion: August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05972135
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Bortezomib\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Lenalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: Expression
 -linked and R-ISS-adapted Stratification for First Line Therapy in Multipl
 e Myeloma Patients\nEstimated primary completion: August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05665140-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT05665140)
DESCRIPTION:Isatuximab\, phase 2/3\, Multiple Myeloma.\nStudy: Expression-l
 inked and R-ISS-adapted Stratification for First Line Therapy in Multiple 
 Myeloma Patients\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05665140
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bortezomib: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\,
  Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated p
 rimary completion: August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3130@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Thalidomide: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Thalidomide\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\
 , Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated 
 primary completion: August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/thalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06464991-3255@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Equecabtagene autoleucel: Phase 3 readout est. (NCT06464991)
DESCRIPTION:Equecabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANB
 A-03)\nEstimated primary completion: August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06464991
URL:https://assetmemo.bio/drug/equecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687004-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Gamgertamig (CM336): Phase 1/2 readout est. (NCT07687004)
DESCRIPTION:Gamgertamig (CM336)\, phase 1/2\, Multiple Myeloma.\nStudy: Son
 rotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amylo
 idosis Based on t(11\;14) Genetic Stratification\nEstimated primary comple
 tion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 gamgertamig-cm336#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07687004
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317416-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270804
DTEND;VALUE=DATE:20270805
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05317416)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Study With El
 ranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple My
 eloma After Transplant\nEstimated primary completion: 4 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05317416
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ci
 ltacabtagene Autoleucel and Talquetamab for the Treatment of Participants 
 With High-Risk Multiple Myeloma\nEstimated primary completion: 26 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550895-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06550895)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of
  Participants With High-Risk Multiple Myeloma\nEstimated primary completio
 n: 26 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ci
 ltacabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06550895
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06376526-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06376526)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: IMMUNOPLANT
  for Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06376526
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181239-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07181239)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336 in Relapsed or Refractory Multiple Myeloma Patients\nEstimated p
 rimary completion: September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07181239
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790474-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04790474)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib-pomalid
 omide-dexamethasone as Second or Third-line Combination Treatment for Pati
 ents With Relapsed and Refractory Multiple Myeloma Previously Treated With
  Daratumumab\, Lenalidomide and Bortezomib\nEstimated primary completion: 
 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ixa
 zomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04790474
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04790474-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04790474)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib-pom
 alidomide-dexamethasone as Second or Third-line Combination Treatment for 
 Patients With Relapsed and Refractory Multiple Myeloma Previously Treated 
 With Daratumumab\, Lenalidomide and Bortezomib\nEstimated primary completi
 on: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04790474
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776395-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04776395)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide Alone or in Combination With Dexamethasone for the Treatment of In
 termediate- or High-Risk Smoldering Multiple Myeloma\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04776395
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Trial That 
 Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible fo
 r Transplant\nEstimated primary completion: 1 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04096066-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04096066)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Trial That
  Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible f
 or Transplant\nEstimated primary completion: 1 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04096066
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04635189-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04635189)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Steroid Spari
 ng Treatment With in Newly Diagnosed Transplant Ineligible Patients With M
 ultiple Myeloma\nEstimated primary completion: 8 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04635189
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04635189-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04635189)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Steroid Spar
 ing Treatment With in Newly Diagnosed Transplant Ineligible Patients With 
 Multiple Myeloma\nEstimated primary completion: 8 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04635189
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Novel Agents in RRMM - Master Protocol\nEstimated prima
 ry completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Is
 atuximab in Combination With Novel Agents in RRMM - Master Protocol\nEstim
 ated primary completion: 13 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3355@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Pegenzileukin: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Pegenzileukin\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuxima
 b in Combination With Novel Agents in RRMM - Master Protocol\nEstimated pr
 imary completion: 13 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pegenzileukin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/pegenzileukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3356@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:SAR439459: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:SAR439459\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab in
  Combination With Novel Agents in RRMM - Master Protocol\nEstimated primar
 y completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sar439459#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/sar439459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04643002-3357@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Evorpacept: Phase 1/2 readout est. (NCT04643002)
DESCRIPTION:Evorpacept\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Novel Agents in RRMM - Master Protocol\nEstimated prima
 ry completion: 13 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/evorpacept#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04643002
URL:https://assetmemo.bio/drug/evorpacept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454187-3217@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SG2918: Phase 1/2 readout est. (NCT07454187)
DESCRIPTION:SG2918\, phase 1/2\, Multiple Myeloma.\nStudy: To Evaluate the 
 Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma\nEs
 timated primary completion: 30 September 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sg2918#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07454187
URL:https://assetmemo.bio/drug/sg2918#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00869232-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT00869232)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: UARK 2008-02 A
  Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Comple
 te Remission\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT00869232
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A Stu
 dy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\n
 Estimated primary completion: October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A S
 tudy Exploring the Use of Early and Late Consolidation/Maintenance Therapy
 \nEstimated primary completion: October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00869232-3130@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT00869232)
DESCRIPTION:Thalidomide\, phase 2\, Multiple Myeloma.\nStudy: UARK 2008-02 
 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Compl
 ete Remission\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT00869232
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3130@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Thalidomide\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06066346-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06066346)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ta
 lquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Ce
 ll Therapy\nEstimated primary completion: October 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06066346
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850234-3183@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT05850234)
DESCRIPTION:AZD0120\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0120 in Rela
 psed/Refractory Multiple Myeloma (DURGA-1)\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd01
 20#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5850234
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in Ul
 tra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Safety and E
 fficacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in 
 Ultra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077895
 22
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828522-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07828522)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: F182112 in C
 ombination With Isatuximab and Lenalidomide for the Treatment of Patients 
 With Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomi
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7828522
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Safety and Eff
 icacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in Ul
 tra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828522-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07828522)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: F182112 in Com
 bination With Isatuximab and Lenalidomide for the Treatment of Patients Wi
 th Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07828
 522
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789522-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07789522)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Safety and Ef
 ficacy of Elranatamab Plus Isatuximab\, Bortezomib\, and Lenalidomide in U
 ltra-High-Risk Multiple Myeloma\nEstimated primary completion: 9 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789522
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828522-3212@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271009
DTEND;VALUE=DATE:20271010
SUMMARY:F182112: Phase 2 readout est. (NCT07828522)
DESCRIPTION:F182112\, phase 2\, Multiple Myeloma.\nStudy: F182112 in Combin
 ation With Isatuximab and Lenalidomide for the Treatment of Patients With 
 Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 9 October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/f182112#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07828522
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, 
 Carfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractory
  Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Carfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04850599-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04850599)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, C
 arfilzomib\, and Pomalidomide for the Treatment of Relapsed or Refractory 
 Multiple Myeloma\nEstimated primary completion: 15 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04850599
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208307-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05208307)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Belantamab M
 afodotin\, Pomalidomide and Dexamethasone for the Treatment of High-Risk M
 yeloma\nEstimated primary completion: 21 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05208307
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208307-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05208307)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Bela
 ntamab Mafodotin\, Pomalidomide and Dexamethasone for the Treatment of Hig
 h-Risk Myeloma\nEstimated primary completion: 21 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05208307
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Bortezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and D
 examethasone in Treating Patients With Relapsed or Refractory Multiple Mye
 loma\nEstimated primary completion: 30 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Ixazomib: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\, Bo
 rtezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and Dexa
 methasone in Treating Patients With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: 30 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\, 
 Bortezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and De
 xamethasone in Treating Patients With Relapsed or Refractory Multiple Myel
 oma\nEstimated primary completion: 30 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stud
 y of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEs
 timated primary completion: November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3122@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:QLS32015: Phase 2 readout est. (NCT07018050)
DESCRIPTION:QLS32015\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study o
 f QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/qls32015#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stu
 dy of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study
  of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stu
 dy of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3369@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:QL2109: Phase 2 readout est. (NCT07018050)
DESCRIPTION:QL2109\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study of 
 QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEstimat
 ed primary completion: November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ql2109#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/ql2109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Trial of Carf
 ilzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After Ste
 m-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nove
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 659293
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02659293-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT02659293)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Trial of Car
 filzomib\, Lenalidomide\, Dexamethasone Versus Lenalidomide Alone After St
 em-cell Transplant for Multiple Myeloma\nEstimated primary completion: Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 02659293
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04975997)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Open-label St
 udy Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd) Versus D
 aratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participants With Rel
 apsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary completion:
  16 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04975997
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT04975997)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ope
 n-label Study Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd
 ) Versus Daratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participant
 s With Relapsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary c
 ompletion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210047-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07210047)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study of H
 uL001 in Relapsed/Refractory Multiple Myeloma Patients\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07210047
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210047-3420@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:HuL001: Phase 1/2 readout est. (NCT07210047)
DESCRIPTION:HuL001\, phase 1/2\, Multiple Myeloma.\nStudy: Study of HuL001 
 in Relapsed/Refractory Multiple Myeloma Patients\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/hul001#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07210047
URL:https://assetmemo.bio/drug/hul001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911748-3432@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:MBS314: Phase 1/2 readout est. (NCT07911748)
DESCRIPTION:MBS314\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of MBS31
 4 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/mbs314#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07911748
URL:https://assetmemo.bio/drug/mbs314#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891809-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04891809)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years
 ) With NDMM\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04891809
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891809-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04891809)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab in 
 Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) 
 With NDMM\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04891809
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04392037-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04392037)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide Combined With Low-dose Cyclophosphamide and Dexamethasone\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04392037
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461988-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06461988)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Talquetamab 
 & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myelom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06461988
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461988-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06461988)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Talquetamab &
  Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06461988
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Selinexor\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessi
 ng Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avai
 lable Therapies in Adult Participants With Relapsed or Refractory Multiple
  Myeloma\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Study Assess
 ing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Ava
 ilable Therapies in Adult Participants With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Etentamig: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06742138)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate 
 the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myelom
 a\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742138-3369@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QL2109: Phase 3 readout est. (NCT06742138)
DESCRIPTION:QL2109\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate the Ef
 ficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ql2109#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06742138
URL:https://assetmemo.bio/drug/ql2109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138209-3122@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS32015: Phase 3 readout est. (NCT07138209)
DESCRIPTION:QLS32015\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparin
 g QLS32015 Monotherapy Versus Pomalidomide\, Dexamethasone (Pd) or Selinex
 or\, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multip
 le Myeloma\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qls32015#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07138209
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, 
 Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple M
 yeloma Not Eligible for Transplant\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729732
 9
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07297329)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to E
 valuate the Safety and Efficacy of SCTC21C in Combination With Bortezomib\
 , Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple
  Myeloma Not Eligible for Transplant\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 97329
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3146@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07297329)
DESCRIPTION:SCTC21C\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evalua
 te the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Len
 alidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myel
 oma Not Eligible for Transplant\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903636-3368@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:QLS4131: Phase 2 readout est. (NCT07903636)
DESCRIPTION:QLS4131\, phase 2\, Multiple Myeloma.\nStudy: QLS4131 for Relap
 sed/Refractory Multiple Myeloma With Extramedullary Disease\nEstimated pri
 mary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/qls4131#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07903636
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06138275-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06138275)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab i
 n R/R Multiple Myeloma\nEstimated primary completion: 1 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06138275
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For 
 High Risk SMM\nEstimated primary completion: 20 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For H
 igh Risk SMM\nEstimated primary completion: 20 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For
  High Risk SMM\nEstimated primary completion: 20 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in A
 dult Participants With Relapsed or Refractory and Lenalidomide-exposed Mul
 tiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0661
 5479
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-3253@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Arlocabtagene autoleucel: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Arlocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy: 
 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard R
 egimens in Adult Participants With Relapsed or Refractory and Lenalidomide
 -exposed Multiple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion
 : 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 rlocabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06615479
URL:https://assetmemo.bio/drug/arlocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03376672-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ixazomib: Phase 2 readout est. (NCT03376672)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib Plus Le
 nalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ixazomib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03376672
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03376672-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT03376672)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Ixazomib Plu
 s Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03376672
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107738-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06107738)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide an
 d Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transpl
 ant for Multiple Myeloma\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06107738
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657312-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07657312)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Infliximab fo
 r Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab 
 Therapy in Patients With Relapsed or Refractory Myeloma\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07657312
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091372-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05091372)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resi
 dual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lena
 lidomide After Autologous Hematopoietic Cell Transplantation in Patients W
 ith Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05091372
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05776979-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05776979)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Post-Transpl
 ant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Mu
 ltiple Myeloma Patients\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05776979
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657312-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07657312)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Infliximab fo
 r Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab 
 Therapy in Patients With Relapsed or Refractory Myeloma\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07657312
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04558931-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04558931)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Clinical Trial
  for Autologus NK Cells Alone or in Combination With Isatuximab as Mainten
 ance for Multiple Myeloma\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04558931
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05776979-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05776979)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Post-Transplan
 t Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Mult
 iple Myeloma Patients\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05776979
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06920251-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06920251)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Phase II Tria
 ls of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab 
 Therapy\nEstimated primary completion: 31 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06920251
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05091372-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05091372)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Mini
 mal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin 
 and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Pa
 tients With Newly Diagnosed Multiple Myeloma\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 elantamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05091372
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107738-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT06107738)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Ce
 ll Transplant for Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0610
 7738
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Testing the U
 se of Combination Therapy in Adult Patients With Newly Diagnosed Multiple 
 Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bortezomib: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Testing the Us
 e of Combination Therapy in Adult Patients With Newly Diagnosed Multiple M
 yeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Testing the 
 Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple
  Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selinexor: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple M
 yeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Sel
 inexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple 
 Myeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nE
 stimated primary completion: January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612787-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT07612787)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Multicent
 er Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed
  Multiple Myeloma\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07612787
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612787-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT07612787)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: A 
 Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With
  Relapsed Multiple Myeloma\nEstimated primary completion: 1 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761
 2787
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Selinexor: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maintena
 nce Therapy in Multiple Myeloma\nEstimated primary completion: 1 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06744894
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ixazomib: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maintenan
 ce Therapy in Multiple Myeloma\nEstimated primary completion: 1 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ixazomib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06744894
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maint
 enance Therapy in Multiple Myeloma\nEstimated primary completion: 1 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0674
 4894
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0305 as
  Monotherapy or in Combination With Anticancer Agents in Participants With
  Multiple Myeloma\nEstimated primary completion: 24 January 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Elranatamab: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Elranatamab\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0305 as 
 Monotherapy or in Combination With Anticancer Agents in Participants With 
 Multiple Myeloma\nEstimated primary completion: 24 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106945-3333@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Vemzatatug vedotin: Phase 1/2 readout est. (NCT06106945)
DESCRIPTION:Vemzatatug vedotin\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0
 305 as Monotherapy or in Combination With Anticancer Agents in Participant
 s With Multiple Myeloma\nEstimated primary completion: 24 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vemzatatug-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06106945
URL:https://assetmemo.bio/drug/vemzatatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Selinexor: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in P
 atients With Multiple Myeloma\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Se
 linexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in
  Patients With Multiple Myeloma\nEstimated primary completion: February 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Se
 linexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in
  Patients With Multiple Myeloma\nEstimated primary completion: February 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of S
 elinexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide i
 n Patients With Multiple Myeloma\nEstimated primary completion: February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0466113
 7
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07421856-3269@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:SENL103: Phase 1/2 readout est. (NCT07421856)
DESCRIPTION:SENL103\, phase 1/2\, Multiple Myeloma.\nStudy: Phase I/II Stud
 y of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter\, 
 Open-Label\, Single-Arm Trial.\nEstimated primary completion: 1 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/senl103#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07421856
URL:https://assetmemo.bio/drug/senl103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009899-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT07009899)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: BCMA Bispec
 ific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)\n
 Estimated primary completion: 1 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07009899
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948084-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06948084)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Medication Combination of Daratumumab and Teclistamab Compa
 red to the Usual Treatment (Daratumumab\, Pomalidomide\, Dexamethasone or 
 Daratumumab\, Carfilzomib\, Dexamethasone) for Patients With High-risk Mul
 tiple Myeloma Refractory or in First Relapse\nEstimated primary completion
 : 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06948084
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948084-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06948084)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Medication Combination of Daratumumab and Teclistamab Compa
 red to the Usual Treatment (Daratumumab\, Pomalidomide\, Dexamethasone or 
 Daratumumab\, Carfilzomib\, Dexamethasone) for Patients With High-risk Mul
 tiple Myeloma Refractory or in First Relapse\nEstimated primary completion
 : 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 eclistamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06948084
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879043-3296@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pamlectabart tismanitin: Phase 1/2 readout est. (NCT04879043)
DESCRIPTION:Pamlectabart tismanitin\, phase 1/2\, Multiple Myeloma.\nStudy:
  Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Mu
 ltiple Myeloma\nEstimated primary completion: March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04879043
URL:https://assetmemo.bio/drug/pamlectabart-tismanitin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05272826)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Iberd
 omide\, Bortezomib\, Dexamethasone With Isatuximab Added on Demand for ND-
 NTE MM Patients\nEstimated primary completion: March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05272826)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Study of Iberd
 omide\, Bortezomib\, Dexamethasone With Isatuximab Added on Demand for ND-
 NTE MM Patients\nEstimated primary completion: March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05272826)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Stu
 dy of Iberdomide\, Bortezomib\, Dexamethasone With Isatuximab Added on Dem
 and for ND-NTE MM Patients\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Carfilzomib: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Carfilzomib\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consoli
 dation After ASCT in NDMM Patients\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06879379
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879379-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pomalidomide: Phase 2/3 readout est. (NCT06879379)
DESCRIPTION:Pomalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: KPD Consol
 idation After ASCT in NDMM Patients\nEstimated primary completion: March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0687937
 9
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530421-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280326
DTEND;VALUE=DATE:20280327
SUMMARY:Venetoclax: Phase 2 readout est. (NCT05530421)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Selinexor\, Ve
 netoclax\, and Dexamethasone (XVenD) in t(11\;14)-Positive Relapsed/Refrac
 tory Multiple Myeloma\nEstimated primary completion: 26 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05530421
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530421-2266@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280326
DTEND;VALUE=DATE:20280327
SUMMARY:Selinexor: Phase 2 readout est. (NCT05530421)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: Selinexor\, Ven
 etoclax\, and Dexamethasone (XVenD) in t(11\;14)-Positive Relapsed/Refract
 ory Multiple Myeloma\nEstimated primary completion: 26 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05530421
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and 
 Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed M
 ultiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and S
 afety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Mu
 ltiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and
  Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed 
 Multiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070459
 09
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and S
 afety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Mu
 ltiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-3142@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Anitocabtagene autoleucel: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Anitocabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Efficacy and Safety of Anitocabtagene Autoleucel in Participants With New
 ly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 itocabtagene-autoleucel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05243797-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Teclistamab: Phase 3 readout est. (NCT05243797)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: Phase 3 Study
  of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Ver
 sus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myelo
 ma as Maintenance Therapy Following Autologous Stem Cell Transplantation\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05243797
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149857-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT07149857)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel\nEst
 imated primary completion: 12 April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07149857
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Minimal Residu
 al Disease-based Strategy With T-Cell Redirector After Treatment With Dara
 tumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly D
 iagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resi
 dual Disease-based Strategy With T-Cell Redirector After Treatment With Da
 ratumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly
  Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485647-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07485647)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Identifying E
 ffective and Cost-Conscious Maintenance Daratumumab Dosing\nEstimated prim
 ary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07485647
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485647-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07485647)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Identifying 
 Effective and Cost-Conscious Maintenance Daratumumab Dosing\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07485647
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585760-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Isatuximab: Phase 2 readout est. (NCT07585760)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus Isa
 tuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment\nEstima
 ted primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07585760
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585760-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07585760)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
  Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairmen
 t\nEstimated primary completion: 1 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07585760
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07312188-3212@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280520
DTEND;VALUE=DATE:20280521
SUMMARY:F182112: Phase 2 readout est. (NCT07312188)
DESCRIPTION:F182112\, phase 2\, Multiple Myeloma.\nStudy: A Study of F18211
 2 in the Treatment of Patients With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: 20 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07312188
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Bortezomib: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Trial on the E
 ffect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Inducti
 on and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (
 GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Trial on the
  Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induc
 tion and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
  (GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03617731-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Isatuximab: Phase 3 readout est. (NCT03617731)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Trial on the E
 ffect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Inducti
 on and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (
 GMMG HD7)\nEstimated primary completion: June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03617731
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391657-3183@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280614
DTEND;VALUE=DATE:20280615
SUMMARY:AZD0120: Phase 3 readout est. (NCT07391657)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparing
  AZD0120\, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) 
 and CD19\, Versus Standard Regimens in Participants With Relapsed Refracto
 ry Multiple Myeloma (DURGA-4)\nEstimated primary completion: 14 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07391657
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181941-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT07181941)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: Response-
 Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed\, Refra
 ctory\, or Triple-Class Relapsed/Refractory Multiple Myeloma\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07181941
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413498-3142@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT06413498)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy i
 n Participants With Relapsed/ Refractory Multiple Myeloma\nEstimated prima
 ry completion: July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06413498
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742215-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07742215)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of th
 e Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patien
 ts With Relapsed or Refractory Multiple Myeloma (AMMADINA)\nEstimated prim
 ary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07742215
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742215-3129@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Torutamig: Phase 3 readout est. (NCT07742215)
DESCRIPTION:Torutamig\, phase 3\, Multiple Myeloma.\nStudy: A Study of the 
 Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients
  With Relapsed or Refractory Multiple Myeloma (AMMADINA)\nEstimated primar
 y completion: July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/torutamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07742215
URL:https://assetmemo.bio/drug/torutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Bela
 ntamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethasone in Re
 lapsed Multiple Myeloma\nEstimated primary completion: 1 July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05789303
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Study of Bel
 antamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethasone in R
 elapsed Multiple Myeloma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05789303
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789303-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05789303)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Stud
 y of Belantamab Mafodotin With Carfilzomib\, Pomalidomide\, and Dexamethas
 one in Relapsed Multiple Myeloma\nEstimated primary completion: 1 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodot
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5789303
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638683-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07638683)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Phase II St
 udy to Evaluate the Efficacy and Safety of Teclistamab in Combination With
  Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurren
 t Light Chain Amyloidosis (MM+AL).\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763868
 3
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638683-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07638683)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: A Phase II St
 udy to Evaluate the Efficacy and Safety of Teclistamab in Combination With
  Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurren
 t Light Chain Amyloidosis (MM+AL).\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763868
 3
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Ev
 aluating the Safety and Efficacy of Multiple Treatments in Participants Wi
 th Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3151@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cevostamab: Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Cevostamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study Eval
 uating the Safety and Efficacy of Multiple Treatments in Participants With
  Multiple Myeloma\nEstimated primary completion: 31 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cevostamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: A
  Study Evaluating the Safety and Efficacy of Multiple Treatments in Partic
 ipants With Multiple Myeloma\nEstimated primary completion: 31 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: COMbination
  Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\nEstimated
  primary completion: August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: COMbination
  Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\nEstimated
  primary completion: August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: C
 OMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Investigate the Safety and Efficacy of Belantamab for the Treatment of Mu
 ltiple Myeloma When Used as Monotherapy and in Combination Treatments\nEst
 imated primary completion: 3 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: A 
 Study to Investigate the Safety and Efficacy of Belantamab for the Treatme
 nt of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
 nts\nEstimated primary completion: 3 August 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714839-3313@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280803
DTEND;VALUE=DATE:20280804
SUMMARY:Belantamab: Phase 1/2 readout est. (NCT05714839)
DESCRIPTION:Belantamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to I
 nvestigate the Safety and Efficacy of Belantamab for the Treatment of Mult
 iple Myeloma When Used as Monotherapy and in Combination Treatments\nEstim
 ated primary completion: 3 August 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/belantamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05714839
URL:https://assetmemo.bio/drug/belantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231629-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05231629)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Sequential Th
 erapy in Multiple Myeloma Guided by MRD Assessments\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05231629
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231629-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05231629)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Sequential Th
 erapy in Multiple Myeloma Guided by MRD Assessments\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/teclistamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05231629
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04808037-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04808037)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: Bl
 mf\, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 8 Septemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/belantamab-m
 afodotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04808037
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratum
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclist
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Bortezomib: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / DS
 MM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5695508
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / 
 DSMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05695508
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Talquetamab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talquet
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Ramantamig: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / DS
 MM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramantam
 ig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5695508
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735637-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07735637)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Phase III\
 , Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compa
 red With ASCT\, in Participants With Newly Diagnosed Multiple Myeloma Who 
 Are Transplant Eligible (DURGA-6).\nEstimated primary completion: 2 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 35637
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735637-3183@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:AZD0120: Phase 3 readout est. (NCT07735637)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Phase III\, Mul
 ticentre Study to Evaluate Consolidation Treatment With AZD0120 Compared W
 ith ASCT\, in Participants With Newly Diagnosed Multiple Myeloma Who Are T
 ransplant Eligible (DURGA-6).\nEstimated primary completion: 2 November 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07735637
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931704-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06931704)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Comparison o
 f Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post
 -transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (
 ElMMA)\nEstimated primary completion: 30 November 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06931704
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931704-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06931704)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Comparison of
  Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-
 transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (E
 lMMA)\nEstimated primary completion: 30 November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06931704
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: International
  Treatment-extension Study in Adult Participants With Multiple Myeloma and
  Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary comp
 letion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/carfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05669989
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Internationa
 l Treatment-extension Study in Adult Participants With Multiple Myeloma an
 d Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary com
 pletion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05669989
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Internationa
 l Treatment-extension Study in Adult Participants With Multiple Myeloma an
 d Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary com
 pletion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05669989
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: International 
 Treatment-extension Study in Adult Participants With Multiple Myeloma and 
 Who Have Derived Clinical Benefit From Isatuximab\nEstimated primary compl
 etion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05669989
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Cevostamab i
 n Combination With Pomalidomide and Dexamethasone Versus Standard of Care 
 in Participants With Previously Treated Multiple Myeloma\nEstimated primar
 y completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07555938
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555938-3151@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cevostamab: Phase 3 readout est. (NCT07555938)
DESCRIPTION:Cevostamab\, phase 3\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone Versus Standard of Care in
  Participants With Previously Treated Multiple Myeloma\nEstimated primary 
 completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cevostamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07555938
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04786028-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04786028)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Isa
 tuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Tr
 eatments in ND-TEMM\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04786028
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216158-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 3 readout est. (NCT06216158)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Iberdomide vs.
  Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnos
 ed Multiple Myeloma\nEstimated primary completion: December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06216158
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216158-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT06216158)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ibe
 rdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06216158
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07569757-3389@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TQB2934: Phase 3 readout est. (NCT07569757)
DESCRIPTION:TQB2934\, phase 3\, Multiple Myeloma.\nStudy: Clinical Study of
  TQB2934 Injection in Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tqb2934#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07569757
URL:https://assetmemo.bio/drug/tqb2934#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258511-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07258511)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecif
 ic Antibody in Participants With Relapsed or Refractory Multiple Myeloma\n
 Estimated primary completion: 12 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07258511
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Bela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/talquetamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isatuximab\, B
 ela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382739-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07382739)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2 Stu
 dy of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in
  Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (
 EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"\nEstimated primary co
 mpletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/elranatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07382739
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922501-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05922501)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Isat
 uximab\, Bela Maf\, Pom\, and Dex in Relapsed/Refractory Multiple Myeloma\
 nEstimated primary completion: 31 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05922501
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732712-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Isatuximab: Phase 2/3 readout est. (NCT07732712)
DESCRIPTION:Isatuximab\, phase 2/3\, Multiple Myeloma.\nStudy: Isa-VRdlite 
 for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Mul
 tiple Myeloma Base on Circulating Plasma Cells\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07732712
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757412-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07757412)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab 
 in Combination With Pomalidomide Administered in Alternative Fashion in Pa
 rticipants With Relapsed or Refractory Multiple Myeloma.\nEstimated primar
 y completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07757412
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757412-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07757412)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Pomalidomide Administered in Alternative Fashion in Par
 ticipants With Relapsed or Refractory Multiple Myeloma.\nEstimated primary
  completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07757412
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085728-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07085728)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Agent Combination of Daratumumab\, Bortezomib\, and Dexamet
 hasone Compared to the Usual Treatment of Cyclophosphamide\, Bortezomib\, 
 and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney
  Failure\nEstimated primary completion: 11 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07085728
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085728-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07085728)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Testing the In
 vestigational Agent Combination of Daratumumab\, Bortezomib\, and Dexameth
 asone Compared to the Usual Treatment of Cyclophosphamide\, Bortezomib\, a
 nd Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney 
 Failure\nEstimated primary completion: 11 January 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07085728
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD0
 120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated pri
 mary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD01
 20 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated prim
 ary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD
 0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated pr
 imary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD01
 20 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated prim
 ary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3183@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:AZD0120: Phase 3 readout est. (NCT07764978)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD0120 
 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated primary
  completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07764978
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579234-3212@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290125
DTEND;VALUE=DATE:20290126
SUMMARY:F182112: Phase 3 readout est. (NCT07579234)
DESCRIPTION:F182112\, phase 3\, Multiple Myeloma.\nStudy: A Multicenter\, R
 andomized\, Open-label\, Parallel-group\, Controlled\, Superiority Phase I
 II Clinical Study Comparing the Efficacy and Safety of F182112 Versus Stan
 dard of Care in Patients With Relapsed or Refractory Multiple Myeloma\nEst
 imated primary completion: 25 January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/f182112#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07579234
URL:https://assetmemo.bio/drug/f182112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\nEstimated primary completion: 31 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\nEstimated primary completion: 31 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\nEstimated primary completion: 31 January 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\nEstimated primary completion: 31 January 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348393-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07348393)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2\, S
 ingle Arm Multicenter\, Study Testing Mezigdomide\, Carfilzomib\, and Dexa
 methasone (480Kd) in Participants With Relapsed or Refractory Multiple Mye
 loma (RRMM)\nEstimated primary completion: February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07348393
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07348393-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT07348393)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: A Phase 2\, S
 ingle Arm Multicenter\, Study Testing Mezigdomide\, Carfilzomib\, and Dexa
 methasone (480Kd) in Participants With Relapsed or Refractory Multiple Mye
 loma (RRMM)\nEstimated primary completion: February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07348393
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Bortezomib: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Bor
 tezomib\, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel\, a C
 AR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and
  Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple 
 Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEstimated primary
  completion: 14 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of B
 ortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel\, a
  CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide a
 nd Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multipl
 e Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEstimated prima
 ry completion: 14 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923893-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT04923893)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Bortezomib\, Lenalidomide and Dexamethasone (VRd) Followed by 
 Cilta-cel\, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by L
 enalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diag
 nosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy\nEs
 timated primary completion: 14 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04923893
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Study of Alter
 native and Approved Dosing Regimens of Belantamab Mafodotin\, Bortezomib\,
  and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple
  Myeloma\nEstimated primary completion: 28 February 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614360-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07614360)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Stud
 y of Alternative and Approved Dosing Regimens of Belantamab Mafodotin\, Bo
 rtezomib\, and Dexamethasone (BVd) in Participants With Relapsed/Refractor
 y Multiple Myeloma\nEstimated primary completion: 28 February 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07614360
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452198-3438@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Velinotamig (GR1803): Phase 3 readout est. (NCT07452198)
DESCRIPTION:Velinotamig (GR1803)\, phase 3\, Multiple Myeloma.\nStudy: A St
 udy of GR1803 Injection Versus Daratumumab\, Pomalidomide\, and Dexamethas
 one (DPd) in Participants With Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: March 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/velinotamig-gr1803#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07452198
URL:https://assetmemo.bio/drug/velinotamig-gr1803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT05896228)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide\, 
 Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Patients With 
 Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: 1 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/carfilzomib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05896
 228
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05896228)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide\, 
 Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Patients With 
 Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: 1 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05896
 228
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05896228)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide\, Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Pati
 ents With Relapsed/Refractory Multiple Myeloma\nEstimated primary completi
 on: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibe
 rdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05896228
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827016-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05827016)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: A S
 tudy to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance The
 rapy Following Autologous Stem Cell Transplant in Participants With Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 15 March 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05827016
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463807-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT07463807)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Testing th
 e Investigational Medication Combination of Teclistamab and Pomalidomide C
 ompared to the Usual Treatment (Carfilzomib\, Pomalidomide\, and Dexametha
 sone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After T
 reatment\nEstimated primary completion: 31 March 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07463807
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463807-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Teclistamab: Phase 1/2 readout est. (NCT07463807)
DESCRIPTION:Teclistamab\, phase 1/2\, Multiple Myeloma.\nStudy: Testing the
  Investigational Medication Combination of Teclistamab and Pomalidomide Co
 mpared to the Usual Treatment (Carfilzomib\, Pomalidomide\, and Dexamethas
 one) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Tr
 eatment\nEstimated primary completion: 31 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07463807
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin in Multi
 ple Myeloma\nEstimated primary completion: April 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Study of C
 arfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin in Mult
 iple Myeloma\nEstimated primary completion: April 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822337-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Belantamab mafodotin: Phase 1/2 readout est. (NCT04822337)
DESCRIPTION:Belantamab mafodotin\, phase 1/2\, Multiple Myeloma.\nStudy: St
 udy of Carfilzomib\, Lenalidomide\, Dexamethasone and Belantamab Mafodotin
  in Multiple Myeloma\nEstimated primary completion: April 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04822337
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab i
 n Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CA
 R T-Cell Therapy in Participants With Previously Treated Multiple Myeloma\
 nEstimated primary completion: 13 April 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825064-3151@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290413
DTEND;VALUE=DATE:20290414
SUMMARY:Cevostamab: Phase 2 readout est. (NCT07825064)
DESCRIPTION:Cevostamab\, phase 2\, Multiple Myeloma.\nStudy: Cevostamab in 
 Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR 
 T-Cell Therapy in Participants With Previously Treated Multiple Myeloma\nE
 stimated primary completion: 13 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cevostamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07825064
URL:https://assetmemo.bio/drug/cevostamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07830485)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus Da
 ratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multip
 le Myeloma\nEstimated primary completion: 15 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07830485)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus D
 aratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multi
 ple Myeloma\nEstimated primary completion: 15 April 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Gamgertamig (CM336): Phase 2 readout est. (NCT07830485)
DESCRIPTION:Gamgertamig (CM336)\, phase 2\, Multiple Myeloma.\nStudy: CM336
  Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnose
 d Multiple Myeloma\nEstimated primary completion: 15 April 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518186-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290429
DTEND;VALUE=DATE:20290430
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07518186)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study Compar
 ing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refracto
 ry Multiple Myeloma\nEstimated primary completion: 29 April 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ramantamig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07518186
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Less Doses of
  Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple 
 Myeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Less Doses of 
 Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple M
 yeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Less Doses o
 f Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple
  Myeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinatio
 n Therapy With Standard-of-Care Combination Regimens in Adult Participants
  With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary compl
 etion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 arfilzomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07222761
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinatio
 n Therapy With Standard-of-Care Combination Regimens in Adult Participants
  With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary compl
 etion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07222761
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to C
 ompare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinati
 on Therapy With Standard-of-Care Combination Regimens in Adult Participant
 s With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary comp
 letion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07222761
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study to Com
 pare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination
  Therapy With Standard-of-Care Combination Regimens in Adult Participants 
 With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary comple
 tion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 rtezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07222761
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinat
 ion Therapy With Standard-of-Care Combination Regimens in Adult Participan
 ts With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary com
 pletion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /linvoseltamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07222761
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623798-3193@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:IBI3003: Phase 3 readout est. (NCT07623798)
DESCRIPTION:IBI3003\, phase 3\, Multiple Myeloma.\nStudy: A Study in Partic
 ipants With Relapsed or Refractory Multiple Myeloma for IBI3003\nEstimated
  primary completion: 31 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ibi3003#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07623798
URL:https://assetmemo.bio/drug/ibi3003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05847569-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT05847569)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Alte
 rnate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of 
 Triple-Class Refractory Multiple Myeloma\nEstimated primary completion: 29
  June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belantama
 b-mafodotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05847569
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligible/Deferred
  Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Isatuximab\,
  Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligible/Deferred
  Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: I
 satuximab\, Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligib
 le/Deferred Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099391-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290724
DTEND;VALUE=DATE:20290725
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07099391)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of 
 Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma\nEstimated pr
 imary completion: 24 July 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07099391
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06171685-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06171685)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: MMRC Horizon 
 One: RRMM (MMRC-099)\nEstimated primary completion: 31 July 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06171685
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993675-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06993675)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Engaging T-ce
 lls to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With T
 alquetmab and Teclistamab (ROTATE)\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06993675
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993675-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06993675)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: Engaging T-ce
 lls to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With T
 alquetmab and Teclistamab (ROTATE)\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06993675
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Carfilzomib: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Carfilzomib\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab in
  Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Ver
 sus KRd in MM\nEstimated primary completion: August 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab i
 n Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Ve
 rsus KRd in MM\nEstimated primary completion: August 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03948035-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT03948035)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Elotuzumab in 
 Combination With Carfilzomib\, Lenalidomide and Dexamethasone (E-KRd) Vers
 us KRd in MM\nEstimated primary completion: August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03948035
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07454382-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07454382)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of El
 ranatamab and Cyclophosphamide in People With Multiple Myeloma\nEstimated 
 primary completion: 27 August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07454382
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06049290-3140@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:LBL-034: Phase 1/2 readout est. (NCT06049290)
DESCRIPTION:LBL-034\, phase 1/2\, Multiple Myeloma.\nStudy: A Clinical Tria
 l of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma\nEstima
 ted primary completion: 20 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lbl-034#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06049290
URL:https://assetmemo.bio/drug/lbl-034#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637578-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07637578)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of El
 ranatamab Outpatient Administration in Patients With Relapsed/Refractory M
 ultiple Myeloma\nEstimated primary completion: October 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07637578
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772024-2849@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Inobrodib: Phase 3 readout est. (NCT07772024)
DESCRIPTION:Inobrodib\, phase 3\, Multiple Myeloma.\nStudy: Inobrodib\, Pom
 alidomide and Dexamethasone Versus Standard Available Therapy in Relapsed 
 or Refractory Multiple Myeloma\nEstimated primary completion: November 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/inobrodib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07772024
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772024-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07772024)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: Inobrodib\, 
 Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: November 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077720
 24
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880601-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06880601)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab P
 lus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple
  Myeloma\nEstimated primary completion: 1 November 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06880601
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05527340-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05527340)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide-de
 xamethasone Alone or in Combination With Standard MM Treatment Regimens in
  Transplant Ineligible Newly Diagnosed Patients.\nEstimated primary comple
 tion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05527340
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05527340-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05527340)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide-dexamethasone Alone or in Combination With Standard MM Treatment R
 egimens in Transplant Ineligible Newly Diagnosed Patients.\nEstimated prim
 ary completion: December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05527340
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711705-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06711705)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab i
 n Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elranatama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 711705
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096778-2849@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Inobrodib: Phase 2 readout est. (NCT07096778)
DESCRIPTION:Inobrodib\, phase 2\, Multiple Myeloma.\nStudy: Inobrodib\, Pom
 alidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\nEs
 timated primary completion: 1 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/inobrodib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07096778
URL:https://assetmemo.bio/drug/inobrodib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07096778-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07096778)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Inobrodib\, 
 Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\
 nEstimated primary completion: 1 December 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07096778
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04240054-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT04240054)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: Bortezomib\, I
 satuximab\, Cyclophosphamide and Dexamethasone Induction in Transplant-Eli
 gible Multiple Myeloma Patients With Renal Insufficiency\nEstimated primar
 y completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04240054
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04240054-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Isatuximab: Phase 2 readout est. (NCT04240054)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Bortezomib\, I
 satuximab\, Cyclophosphamide and Dexamethasone Induction in Transplant-Eli
 gible Multiple Myeloma Patients With Renal Insufficiency\nEstimated primar
 y completion: 1 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/isatuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04240054
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933432-3368@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:QLS4131: Phase 3 readout est. (NCT07933432)
DESCRIPTION:QLS4131\, phase 3\, Multiple Myeloma.\nStudy: A Study in Partic
 ipants With Relapsed or Refractory Multiple Myeloma for QLS4131\nEstimated
  primary completion: 14 December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/qls4131#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07933432
URL:https://assetmemo.bio/drug/qls4131#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207799-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06207799)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Pre-transpla
 nt Purging and Post-transplant MRD-guided Maintenance Therapy With Elranat
 amab in Patients With High-risk Multiple Myeloma\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06207799
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207799-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06207799)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Pre-transplan
 t Purging and Post-transplant MRD-guided Maintenance Therapy With Elranata
 mab in Patients With High-risk Multiple Myeloma\nEstimated primary complet
 ion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/elranatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06207799
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937635-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT03937635)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Lenalidomide\
 , and Dexamethasone With or Without Daratumumab in Treating Patients With 
 High-Risk Smoldering Myeloma\nEstimated primary completion: 31 December 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03937635
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937635-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT03937635)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Lenalidomide
 \, and Dexamethasone With or Without Daratumumab in Treating Patients With
  High-Risk Smoldering Myeloma\nEstimated primary completion: 31 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0393763
 5
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998786-2848@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Ixazomib: Phase 2 readout est. (NCT04998786)
DESCRIPTION:Ixazomib\, phase 2\, Multiple Myeloma.\nStudy: A Multi-center O
 pen-label Phase 2 Study of Ixazomib\, Iberdomide and Dexamethasone in Elde
 rly Patients With Multiple Myeloma at First Relapse."\nEstimated primary c
 ompletion: 1 January 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ixazomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04998786
URL:https://assetmemo.bio/drug/ixazomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998786-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04998786)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: A M
 ulti-center Open-label Phase 2 Study of Ixazomib\, Iberdomide and Dexameth
 asone in Elderly Patients With Multiple Myeloma at First Relapse."\nEstima
 ted primary completion: 1 January 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04998786
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07284758-3232@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Cemsidomide: Phase 2 readout est. (NCT07284758)
DESCRIPTION:Cemsidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Re
 lapsed/Refractory Multiple Myeloma\nEstimated primary completion: March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cemsidomide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07284758
URL:https://assetmemo.bio/drug/cemsidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immun
 e HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimate
 d primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Talquetamab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/talquetamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3157@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Gamgertamig (CM336): Phase 3 readout est. (NCT07910903)
DESCRIPTION:Gamgertamig (CM336)\, phase 3\, Multiple Myeloma.\nStudy: Study
  of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: May 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/gamgertamig-cm336#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910903-3258@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Lumrotatug: Phase 3 readout est. (NCT07910903)
DESCRIPTION:Lumrotatug\, phase 3\, Multiple Myeloma.\nStudy: Study of CM336
 +CM313 Combination Therapy in Patients With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lumrotatug#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07910903
URL:https://assetmemo.bio/drug/lumrotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500884-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Ramantamig: Phase 2 readout est. (NCT06500884)
DESCRIPTION:Ramantamig\, phase 2\, Multiple Myeloma.\nStudy: A Study to Eva
 luate Preventive Treatments for GPRC5D-related Oral Events\nEstimated prim
 ary completion: 30 May 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ramantamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06500884
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116616-3373@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300617
DTEND;VALUE=DATE:20300618
SUMMARY:mRNA-2808: Phase 1/2 readout est. (NCT07116616)
DESCRIPTION:mRNA-2808\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of mR
 NA-2808 in Participants With Relapsed or Refractory Multiple Myeloma\nEsti
 mated primary completion: 17 June 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/mrna-2808#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07116616
URL:https://assetmemo.bio/drug/mrna-2808#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469893-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05469893)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Immuno-PRISM 
 (PRecision Intervention Smoldering Myeloma)\nEstimated primary completion:
  31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclis
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05469893
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Carfilzomib: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Carfilzomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to Ev
 aluate the Efficacy and Safety of Belantamab Mafodotin in Combination With
  Standard of Care in Participants With Relapsed-Refractory Multiple Myelom
 a (RRMM)\nEstimated primary completion: 30 August 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study to E
 valuate the Efficacy and Safety of Belantamab Mafodotin in Combination Wit
 h Standard of Care in Participants With Relapsed-Refractory Multiple Myelo
 ma (RRMM)\nEstimated primary completion: 30 August 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study to Eva
 luate the Efficacy and Safety of Belantamab Mafodotin in Combination With 
 Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma
  (RRMM)\nEstimated primary completion: 30 August 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227311-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07227311)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combina
 tion With Standard of Care in Participants With Relapsed-Refractory Multip
 le Myeloma (RRMM)\nEstimated primary completion: 30 August 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07227311
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Bortezomib: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Dif
 ferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumuma
 b and Teclistamab in Combination With Daratumumab Following Induction With
  Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participants
  With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary co
 mpletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06577025
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: A Study of D
 ifferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumu
 mab and Teclistamab in Combination With Daratumumab Following Induction Wi
 th Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participan
 ts With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary 
 completion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Talquetamab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Talquetamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/talquetamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  A Study of Different Sequences of Cilta-cel\, Talquetamab in Combination 
 With Daratumumab and Teclistamab in Combination With Daratumumab Following
  Induction With Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone 
 in Participants With Standard-risk Newly Diagnosed Multiple Myeloma\nEstim
 ated primary completion: 2 September 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665450-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07665450)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Ra
 mantamig Plus Daratumumab Versus Daratumumab\, Bortezomib\, Lenalidomide\,
  and Dexamethasone (DVRd) or Daratumumab\, Lenalidomide\, and Dexamethason
 e (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Pla
 nned\nEstimated primary completion: 4 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07665450
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665450-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07665450)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Study of Ram
 antamig Plus Daratumumab Versus Daratumumab\, Bortezomib\, Lenalidomide\, 
 and Dexamethasone (DVRd) or Daratumumab\, Lenalidomide\, and Dexamethasone
  (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Plan
 ned\nEstimated primary completion: 4 September 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramantamig#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07665450
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997081-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06997081)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: ERd Combinat
 ion Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)\nEstimated
  primary completion: 30 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06997081
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997081-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06997081)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ERd Combinati
 on Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)\nEstimated 
 primary completion: 30 September 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06997081
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Isatuximab i
 n Combination With Lenalidomide and Dexamethasone in High-risk Smoldering 
 Multiple Myeloma\nEstimated primary completion: 14 October 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Isatuximab: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: Isatuximab in 
 Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Mu
 ltiple Myeloma\nEstimated primary completion: 14 October 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/isatuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab\, Daratumumab and 
 Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and D
 examethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not
  Candidates for Transplant\nEstimated primary completion: 18 October 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to L
 earn About the Effects of the Combination of Elranatamab\, Daratumumab and
  Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and 
 Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are No
 t Candidates for Transplant\nEstimated primary completion: 18 October 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Elranatamab: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab\, Daratumumab and 
 Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and D
 examethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not
  Candidates for Transplant\nEstimated primary completion: 18 October 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax A
 lone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in
  Adult Participants With Multiple Myeloma (MM)\nEstimated primary completi
 on: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06953960
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alo
 ne or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in A
 dult Participants With Multiple Myeloma (MM)\nEstimated primary completion
 : December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eten
 tamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06953960
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-3279@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Surzetoclax: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Surzetoclax\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax A
 lone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in
  Adult Participants With Multiple Myeloma (MM)\nEstimated primary completi
 on: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 rzetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06953960
URL:https://assetmemo.bio/drug/surzetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695740-3274@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:YKST02: Phase 2 readout est. (NCT07695740)
DESCRIPTION:YKST02\, phase 2\, Multiple Myeloma.\nStudy: Study of YKST02 in
  Adults With Relapsed or Refractory Multiple Myeloma\nEstimated primary co
 mpletion: December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ykst02#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07695740
URL:https://assetmemo.bio/drug/ykst02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771361-3309@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:LMY-920: Phase 2 readout est. (NCT07771361)
DESCRIPTION:LMY-920\, phase 2\, Multiple Myeloma.\nStudy: BAFF CAR-T Cells 
 (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and
  Multiple Myeloma\nEstimated primary completion: December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lmy-920#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07771361
URL:https://assetmemo.bio/drug/lmy-920#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05344833-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05344833)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Post-Autolog
 ous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Res
 idual Disease Positive Multiple Myeloma\nEstimated primary completion: Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidom
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05344833
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05344833-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05344833)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Post-Autologou
 s Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Resid
 ual Disease Positive Multiple Myeloma\nEstimated primary completion: Decem
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0534
 4833
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elr
 anatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnos
 ed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary comp
 letion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07247097
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Bortezomib: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elra
 natamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnose
 d Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary compl
 etion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07247097
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: El
 ranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagno
 sed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary com
 pletion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07247097
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elr
 anatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnos
 ed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary comp
 letion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/elranatamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07247097
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187441-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06187441)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: FeAsiBility o
 f a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Da
 ratumumab-lenalidomide-dexamethasone (HOVON174MM)\nEstimated primary compl
 etion: January 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06187441
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187441-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06187441)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: FeAsiBility 
 of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With D
 aratumumab-lenalidomide-dexamethasone (HOVON174MM)\nEstimated primary comp
 letion: January 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06187441
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DSM
 M XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DSM
 M XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DS
 MM XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681596-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Modular\,
  Phase I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With
  Relapsed or Refractory Multiple Myeloma\nEstimated primary completion: 6 
 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7681596
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681596-3202@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:AZD4045: Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:AZD4045\, phase 1/2\, Multiple Myeloma.\nStudy: A Modular\, Pha
 se I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With Rel
 apsed or Refractory Multiple Myeloma\nEstimated primary completion: 6 Marc
 h 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd4045#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07681596
URL:https://assetmemo.bio/drug/azd4045#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Elotuzumab\
 , Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment of Relaps
 ed Multiple Myeloma\nEstimated primary completion: 1 April 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-3132@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: Elotuzumab\,
  Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment of Relapse
 d Multiple Myeloma\nEstimated primary completion: 1 April 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: E
 lotuzumab\, Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment
  of Relapsed Multiple Myeloma\nEstimated primary completion: 1 April 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of B
 elantamab Mafodotin Administered in Combination With Lenalidomide and Dexa
 methasone (BRd) Versus Daratumumab\, Lenalidomide\, and Dexamethasone (DRd
 ) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ine
 ligible for Autologous Stem Cell Transplantation (TI-NDMM)\nEstimated prim
 ary completion: 28 April 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06679101
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679101-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Belantamab mafodotin: Phase 3 readout est. (NCT06679101)
DESCRIPTION:Belantamab mafodotin\, phase 3\, Multiple Myeloma.\nStudy: A St
 udy of Belantamab Mafodotin Administered in Combination With Lenalidomide 
 and Dexamethasone (BRd) Versus Daratumumab\, Lenalidomide\, and Dexamethas
 one (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who
  Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)\nEstima
 ted primary completion: 28 April 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06679101
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Teclistamab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 eclistamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of T
 eclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and T
 alquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Pa
 rticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary comple
 tion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05552222
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Talquetamab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 alquetamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2078@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Co
 mbination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With an
 d Without Bortezomib) in Participants With Relapsed or Refractory Multiple
  Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Bortezomib: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Bortezomib\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/bortezomib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05561387-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05561387)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Comparing Com
 binations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a
  Stem Cell Transplant is Not a Medically Suitable Treatment\nEstimated pri
 mary completion: 30 May 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05561387
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05561387-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05561387)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Comparing Co
 mbinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When 
 a Stem Cell Transplant is Not a Medically Suitable Treatment\nEstimated pr
 imary completion: 30 May 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05561387
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740486-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07740486)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Treatment With Teclistamab and Talquetamab Versus Daratumumab and Len
 alidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who
  Still Have Detectable Disease\nEstimated primary completion: June 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07740486
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740486-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Talquetamab: Phase 3 readout est. (NCT07740486)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Treatment With Teclistamab and Talquetamab Versus Daratumumab and Len
 alidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who
  Still Have Detectable Disease\nEstimated primary completion: June 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07740486
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513639-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Carfilzomib: Phase 2/3 readout est. (NCT04513639)
DESCRIPTION:Carfilzomib\, phase 2/3\, Multiple Myeloma.\nStudy: The Relapse
  from MRD Negativity As Indication for Treatment (REMNANT) Study\nEstimate
 d primary completion: 1 June 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04513639
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513639-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT04513639)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: The Relapse
  from MRD Negativity As Indication for Treatment (REMNANT) Study\nEstimate
 d primary completion: 1 June 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04513639
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940297-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20310815
DTEND;VALUE=DATE:20310816
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06940297)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients 
 With Relapsed or Refractory Multiple Myeloma\nEstimated primary completion
 : 15 August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cil
 tacabtagene-autoleucel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06940297
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Belantamab Maf
 odotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamethasone for
  Newly Diagnosed Multiple Myeloma\nEstimated primary completion: November 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07285239
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Belantamab M
 afodotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamethasone f
 or Newly Diagnosed Multiple Myeloma\nEstimated primary completion: Novembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 5239
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285239-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Belantamab mafodotin: Phase 3 readout est. (NCT07285239)
DESCRIPTION:Belantamab mafodotin\, phase 3\, Multiple Myeloma.\nStudy: Bela
 ntamab Mafodotin or Daratumumab With Bortezomib\, Lenalidomide and Dexamet
 hasone for Newly Diagnosed Multiple Myeloma\nEstimated primary completion:
  November 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/belan
 tamab-mafodotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07285239
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901868-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Mezigdomide: Phase 2 readout est. (NCT07901868)
DESCRIPTION:Mezigdomide\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab W
 ith Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Mul
 tiple Myeloma\nEstimated primary completion: December 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07901868
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901868-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Elranatamab: Phase 2 readout est. (NCT07901868)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Elranatamab W
 ith Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Mul
 tiple Myeloma\nEstimated primary completion: December 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07901868
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06182774-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06182774)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Fixed Durati
 on vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Ol
 der Adults With Newly-Diagnosed Multiple Myeloma\nEstimated primary comple
 tion: 31 January 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06182774
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140524-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320518
DTEND;VALUE=DATE:20320519
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06140524)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma
  Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk 
 Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smolde
 ring Multiple Myeloma\nEstimated primary completion: 18 May 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06140524
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483100-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06483100)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Measurable Re
 sidual Disease-Guided Post-Transplant Elranatamab Maintenance\nEstimated p
 rimary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06483100
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04071457-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04071457)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: S1803\, Lenal
 idomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to D
 irect Therapy Duration\nEstimated primary completion: September 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04071457
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06574126-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06574126)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Ciltacabtagen
 e Autoleucel in High-Risk Smoldering Multiple Myeloma\nEstimated primary c
 ompletion: 30 September 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06574126
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06574126-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Ciltacabtagene autoleucel: Phase 2 readout est. (NCT06574126)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 2\, Multiple Myeloma.\nStudy:
  Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma\nEstim
 ated primary completion: 30 September 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06574126
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-c
 ell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resid
 ual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple My
 eloma\nEstimated primary completion: November 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-
 cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resi
 dual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple M
 yeloma\nEstimated primary completion: November 2032. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Elranatamab: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Elranatamab\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-c
 ell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resid
 ual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple My
 eloma\nEstimated primary completion: November 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/elranatamab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06910124-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20321202
DTEND;VALUE=DATE:20321203
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT06910124)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Linvoseltama
 b in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to D
 eepen Responses or Redrive MRD Negativity After Relapse\nEstimated primary
  completion: 2 December 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06910124
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06910124-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20321202
DTEND;VALUE=DATE:20321203
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06910124)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: Linvoseltam
 ab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to 
 Deepen Responses or Redrive MRD Negativity After Relapse\nEstimated primar
 y completion: 2 December 2032. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06910124
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955508-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330125
DTEND;VALUE=DATE:20330126
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT05955508)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult P
 articipants With Smoldering Multiple Myeloma at High Risk of Developing Mu
 ltiple Myeloma\nEstimated primary completion: 25 January 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05955508
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728188-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Pomalidomide: Phase 3 readout est. (NCT07728188)
DESCRIPTION:Pomalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to E
 valuate Adverse Events and Change in Disease Activity With Injected Etenta
 mig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relaps
 ed or Refractory Multiple Myeloma\nEstimated primary completion: February 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pomalidomide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077281
 88
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728188-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Etentamig: Phase 3 readout est. (NCT07728188)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eval
 uate Adverse Events and Change in Disease Activity With Injected Etentamig
  Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed 
 or Refractory Multiple Myeloma\nEstimated primary completion: February 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07728188
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748689-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Pomalidomide: Phase 2 readout est. (NCT07748689)
DESCRIPTION:Pomalidomide\, phase 2\, Multiple Myeloma.\nStudy: Comparing Lo
 wer Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and De
 xamethasone in Relapsed or Refractory Multiple Myeloma.\nEstimated primary
  completion: March 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pomalidomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07748689
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748689-3152@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Belantamab mafodotin: Phase 2 readout est. (NCT07748689)
DESCRIPTION:Belantamab mafodotin\, phase 2\, Multiple Myeloma.\nStudy: Comp
 aring Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomid
 e and Dexamethasone in Relapsed or Refractory Multiple Myeloma.\nEstimated
  primary completion: March 2033. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/belantamab-mafodotin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07748689
URL:https://assetmemo.bio/drug/belantamab-mafodotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03761108-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330330
DTEND;VALUE=DATE:20330331
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT03761108)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: Phase 1/2
  Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Mult
 iple Myeloma\nEstimated primary completion: 30 March 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03761108
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05730036-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330419
DTEND;VALUE=DATE:20330420
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT05730036)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Trial to 
 Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzum
 ab\, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/R
 efractory Multiple Myeloma\nEstimated primary completion: 19 April 2033. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05730036
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145400-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330528
DTEND;VALUE=DATE:20330529
SUMMARY:Lenalidomide: Phase 2 readout est. (NCT05145400)
DESCRIPTION:Lenalidomide\, phase 2\, Multiple Myeloma.\nStudy: Isa-Rd for F
 rail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma\nEst
 imated primary completion: 28 May 2033. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05145400
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05145400-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330528
DTEND;VALUE=DATE:20330529
SUMMARY:Isatuximab: Phase 2 readout est. (NCT05145400)
DESCRIPTION:Isatuximab\, phase 2\, Multiple Myeloma.\nStudy: Isa-Rd for Fra
 il and/or Much Older Patients With Newly Diagnosed Multiple Myeloma\nEstim
 ated primary completion: 28 May 2033. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/isatuximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05145400
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed by
  Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide 
 and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT
 ) in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primary
  completion: June 2033. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05257083
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Bortezomib: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Study of Dar
 atumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed by 
 Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide a
 nd Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT)
  in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primary 
 completion: June 2033. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05257083
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study of D
 aratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed b
 y Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide
  and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASC
 T) in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primar
 y completion: June 2033. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05257083
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-3161@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Ciltacabtagene autoleucel: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Ciltacabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Study of Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVR
 d) Followed by Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\,
  Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Tr
 ansplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma\nEst
 imated primary completion: June 2033. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05257083
URL:https://assetmemo.bio/drug/ciltacabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Personalisin
 g Treatment for Myeloma Patients Based on Initial Response to NHS Treatmen
 t and Their Overall Fitness Level\nEstimated primary completion: June 2033
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/lenalidomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Talquetamab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Talquetamab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/talquetamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393282-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330727
DTEND;VALUE=DATE:20330728
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07393282)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Mu
 ltiple Myeloma (HR-SMM)\nEstimated primary completion: 27 July 2033. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07393282
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratu
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3124@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Teclistamab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Teclistamab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclis
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Bortezomib: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Bortezomib\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing Bi
 specific Antibody Treatment to Autologous Stem Cell Transplant for Newly D
 iagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 1
  August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezo
 mib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07887984
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Lenalidomide: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Lenalidomide\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing 
 Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly
  Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion:
  1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenal
 idomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07887984
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3135@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Talquetamab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Talquetamab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/talque
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/talquetamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455851-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT07455851)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Trial t
 o Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Ad
 ult Participants With Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: 30 September 2033. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07455851
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455851-3163@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:REGN17372: Phase 1/2 readout est. (NCT07455851)
DESCRIPTION:REGN17372\, phase 1/2\, Multiple Myeloma.\nStudy: A Trial to St
 udy if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult 
 Participants With Relapsed/Refractory Multiple Myeloma\nEstimated primary 
 completion: 30 September 2033. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/regn17372#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07455851
URL:https://assetmemo.bio/drug/regn17372#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Iber-
 VD Induction\, Followed by Risk & Response Adapted Consolidation & Mainten
 ance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Octobe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezomib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076245
 13
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Iber-
 VD Induction\, Followed by Risk & Response Adapted Consolidation & Mainten
 ance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Octobe
 r 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/isatuximab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076245
 13
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Ib
 er-VD Induction\, Followed by Risk & Response Adapted Consolidation & Main
 tenance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Oct
 ober 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07624513
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT07624513)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: D2 
 - Isa-Iber-VD Induction\, Followed by Risk & Response Adapted Consolidatio
 n & Maintenance\, in Transplant-Eligible NDMM\nEstimated primary completio
 n: 1 October 2033. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ib
 erdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07624513
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669247-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331111
DTEND;VALUE=DATE:20331112
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT06669247)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study t
 o Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination Wit
 h Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 11 November 2033. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06669247
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669247-3407@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20331111
DTEND;VALUE=DATE:20331112
SUMMARY:REGN7945: Phase 1/2 readout est. (NCT06669247)
DESCRIPTION:REGN7945\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to Ass
 ess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Lin
 voseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
 \nEstimated primary completion: 11 November 2033. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/regn7945#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06669247
URL:https://assetmemo.bio/drug/regn7945#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828511-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351102
DTEND;VALUE=DATE:20351103
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT05828511)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Window 
 of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated\
 , and How Well it Works in Adult Participants With Recently Diagnosed Mult
 iple Myeloma Who Have Not Already Received Treatment\nEstimated primary co
 mpletion: 2 November 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/linvoseltamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05828511
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-2284@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Carfilzomib: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Carfilzomib\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/carfilzomib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/carfilzomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3025@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Mezigdomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Mezigdomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/mezigdomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/mezigdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3123@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Pomalidomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Pomalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Assess Change in Disease Activity and Adverse Events (AE)s in Adult Parti
 cipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific An
 tibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\n
 Estimated primary completion: December 2035. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pomalidomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/pomalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to
  Assess Change in Disease Activity and Adverse Events (AE)s in Adult Parti
 cipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific An
 tibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\n
 Estimated primary completion: December 2035. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3209@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: A
  Study to Assess Change in Disease Activity and Adverse Events (AE)s in Ad
 ult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-sp
 ecific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combi
 nations\nEstimated primary completion: December 2035. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Change in Disease Activity and Adverse Events (AE)s in Adult Particip
 ants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antib
 odies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nEst
 imated primary completion: December 2035. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3278@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:ABBV-2001: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:ABBV-2001\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Change in Disease Activity and Adverse Events (AE)s in Adult Particip
 ants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antib
 odies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nEst
 imated primary completion: December 2035. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abbv-2001#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/abbv-2001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/L
 enalidomide Consolidation and/or Elranatamab Maintenance Versus Standard o
 f Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimat
 ed primary completion: May 2036. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Bortezomib: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/Le
 nalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of
  Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimate
 d primary completion: May 2036. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bortezomib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/
 Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard 
 of Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstima
 ted primary completion: May 2036. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lenalidomide#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-3143@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Elranatamab: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Elranatamab\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/L
 enalidomide Consolidation and/or Elranatamab Maintenance Versus Standard o
 f Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimat
 ed primary completion: May 2036. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elranatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/elranatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Bortezomib: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Bortezomib\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-V
 Rd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comple
 tion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bortezomib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07600151
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Lenalidomide: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Lenalidomide\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa
 -VRd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comp
 letion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lenalidomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07600151
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Isatuximab: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Isatuximab\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-V
 Rd in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary comple
 tion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/isatuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07600151
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-VR
 d in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary complet
 ion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/etentamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07600151
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn How Safe and How Well Linvoseltamab Works Compared to Standard Treatme
 nt in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transp
 lant\nEstimated primary completion: December 2036. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Study to L
 earn How Safe and How Well Linvoseltamab Works Compared to Standard Treatm
 ent in Adult Patients With Multiple Myeloma Who Are Not Eligible for Trans
 plant\nEstimated primary completion: December 2036. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenalidomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-3159@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treat
 ment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Tran
 splant\nEstimated primary completion: December 2036. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903272-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20370111
DTEND;VALUE=DATE:20370112
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07903272)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Trial Compa
 ring Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab\, Bortez
 omib\, Lenalidomide\, and Dexamethasone in Participants With Newly Diagnos
 ed Multiple Myeloma Who Are Transplant Eligible\nEstimated primary complet
 ion: 11 January 2037. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07903272
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903272-3310@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20370111
DTEND;VALUE=DATE:20370112
SUMMARY:Ramantamig: Phase 3 readout est. (NCT07903272)
DESCRIPTION:Ramantamig\, phase 3\, Multiple Myeloma.\nStudy: A Trial Compar
 ing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab\, Bortezo
 mib\, Lenalidomide\, and Dexamethasone in Participants With Newly Diagnose
 d Multiple Myeloma Who Are Transplant Eligible\nEstimated primary completi
 on: 11 January 2037. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ramantamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07903272
URL:https://assetmemo.bio/drug/ramantamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate Sa
 fety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell
  Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bort
 ezomib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07903506
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate 
 Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Ce
 ll Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary compl
 etion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/le
 nalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07903506
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3136@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Isatuximab: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Isatuximab\, phase 3\, Multiple Myeloma.\nStudy: To Evaluate Sa
 fety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell
  Transplant in Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: March 2039. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/isat
 uximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07903506
URL:https://assetmemo.bio/drug/isatuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903506-3142@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20390331
DTEND;VALUE=DATE:20390401
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07903506)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autol
 ogous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma\nEstimated 
 primary completion: March 2039. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07903506
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095452-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20410331
DTEND;VALUE=DATE:20410401
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT07095452)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: A Study to 
 Assess A Change in Disease Activity and Adverse Events of Intravenous Eten
 tamig and Daratumumab (Etentamig+D) Compared to Daratumumab\, Lenalidomide
 \, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Mult
 iple Myeloma Not Eligible for Transplant\nEstimated primary completion: Ma
 rch 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 95452
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095452-3229@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20410331
DTEND;VALUE=DATE:20410401
SUMMARY:Etentamig: Phase 2/3 readout est. (NCT07095452)
DESCRIPTION:Etentamig\, phase 2/3\, Multiple Myeloma.\nStudy: A Study to As
 sess A Change in Disease Activity and Adverse Events of Intravenous Etenta
 mig and Daratumumab (Etentamig+D) Compared to Daratumumab\, Lenalidomide\,
  and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multip
 le Myeloma Not Eligible for Transplant\nEstimated primary completion: Marc
 h 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0709545
 2
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-2289@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Trial to Ev
 aluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of
  Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: F
 ebruary 2042. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratum
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07887672
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3125@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Bortezomib: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Bortezomib\, phase 3\, Multiple Myeloma.\nStudy: A Trial to Eva
 luate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of 
 Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: Fe
 bruary 2042. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bortezom
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7887672
URL:https://assetmemo.bio/drug/bortezomib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3126@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Lenalidomide: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Lenalidomide\, phase 3\, Multiple Myeloma.\nStudy: A Trial to E
 valuate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard o
 f Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 
 February 2042. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenali
 domide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07887672
URL:https://assetmemo.bio/drug/lenalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-3142@assetmemo.bio
DTSTAMP:20261121T004025Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Anitocabtagene autoleucel: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Anitocabtagene autoleucel\, phase 3\, Multiple Myeloma.\nStudy:
  A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Vers
 us Standard of Care in Newly Diagnosed Multiple Myeloma\nEstimated primary
  completion: February 2042. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/anitocabtagene-autoleucel#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07887672
URL:https://assetmemo.bio/drug/anitocabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
